AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26052866 — intervention group
Group type: COMPARATOR
Intervention: Warfarin qd
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban (all doses)
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban
Number of subjects: 1297
Study 23584270 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional overlay
Number of subjects: 72
Study 23584270 — intervention group
Group type: COMPARATOR
Intervention: Gel group (control)
Number of subjects: 72
Study 22118256 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 7
Study 22118256 — intervention group
Group type: COMPARATOR
Intervention: Tilt-table standing (TTS)
Number of subjects: 7
Study 19114261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation combined with cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 21
Study 17145604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (specifics not provided)
Number of subjects: 0
Study 17145604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter randomized controlled trials (not yet conducted)
Number of subjects: 0
Study 15317636 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention (BBI) based on the Blood‐Borne Virus Transmission Risk Assessment Questionnaire (BBV‐TRAQ), tailored 30-minute session
Number of subjects: 145
Study 15317636 — intervention group
Group type: COMPARATOR
Intervention: Standardized educational intervention
Number of subjects: 145
Study 11342997 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 200 mg tid for six months
Number of subjects: 181
Study 11342997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 7943509 — intervention group
Group type: EXPERIMENTAL
Intervention: semirigid ankle stabilizer
Number of subjects: 1601
Study 3069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (PZ) 30 mg i.m.
Number of subjects: 11
Study 3069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 50 mg p.o.
Number of subjects: 11
Study 3069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic AMI + acute PZ
Number of subjects: 11
Study 3069477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3069477 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic AMI
Number of subjects: 11
Study 1703428 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 81
Study 1703428 — intervention group
Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 81
Study 4899996 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenacetin
Number of subjects: 0
Study 4899996 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 4899996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 31627998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 8mg transdermal patch at bedtime
Number of subjects: 63
Study 31627998 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 63
Study 30782208 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyejigachulbutang (2.5 g three times a day for 4 weeks)
Number of subjects: 80
Study 30782208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.5 g three times a day for 4 weeks)
Number of subjects: 80
Study 28808144 — intervention group
Group type: EXPERIMENTAL
Intervention: Real air purifiers
Number of subjects: 55
Study 28808144 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 55
Study 27326445 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 27326445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 27326445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (titrated dose)
Number of subjects: 0
Study 27326445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (pretreatment)
Number of subjects: 0
Study 27326445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (timing of administration)
Number of subjects: 0
Study 24061784 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks, with a mean maximum dose of 16.5 mg daily (maximum 20 mg/d)
Number of subjects: 149
Study 24061784 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 149
Study 21571150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (20 mg/kg per day for 2 years)
Number of subjects: 193
Study 21571150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 19713405 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 40
Study 19713405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Number of subjects: 40
Study 16765007 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (PMEA) measured using LC-MS/MS method in human serum
Number of subjects: 0
Study 16765007 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (PMEA) measured using LC-MS/MS method in human urine
Number of subjects: 0
Study 12757688 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil
Number of subjects: 320
Study 12757688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 320
Study 12757688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil
Number of subjects: 320
Study 12757688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis or other drugs)
Number of subjects: 320
Study 11516001 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with overdentures
Number of subjects: 10
Study 11516001 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of implants with overdentures
Number of subjects: 10
Study 9767835 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical technique for saphenous vein dissection (Group I)
Number of subjects: 60
Study 9767835 — intervention group
Group type: COMPARATOR
Intervention: Video-surgery technique for saphenous vein dissection (Group II)
Number of subjects: 60
Study 8144761 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 301
Study 8144761 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study 3345278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 0
Study 3345278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (effective doses)
Number of subjects: 0
Study 31702419 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EI (Methotrexate-Etoposide-Ifosfamide)
Number of subjects: 95
Study 31702419 — intervention group
Group type: COMPARATOR
Intervention: API-AI (Doxorubicin-Cisplatin-Ifosfamide)
Number of subjects: 95
Study 31702419 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EI and API-AI
Number of subjects: 95
Study 28901219 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Wellness Coaching
Number of subjects: 320
Study 28901219 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 26585393 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST) as add-on to standard outpatient rehabilitation
Number of subjects: 166
Study 26585393 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient rehabilitation only
Number of subjects: 166
Study 25403813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 128
Study 25403813 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educative coaching group (OCD-EP)
Number of subjects: 128
Study 24347774 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitfield's ointment + oral fluconazole (150 mg once a week for 4 weeks)
Number of subjects: 120
Study 24347774 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% butenafine
Number of subjects: 120
Study 24347774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 20492850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/d
Number of subjects: 70
Study 20492850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18446591 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based administration of preventive asthma medications with dose adjustments according to NHLBI guidelines and a home-based ETS reduction program utilizing motivational interviewing principles.
Number of subjects: 0
Study 16770112 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara tablet 2.5 mg) given orally once daily
Number of subjects: 0
Study 16770112 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara tablet 2.5 mg)
Number of subjects: 0
Study 12727970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with Premarin or a mixture of estrone and equilin sulfates for 3 months
Number of subjects: 0
Study 12727970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 12727970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen in the proliferative phase
Number of subjects: 0
Study 12727970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen in the secretory phase
Number of subjects: 0
Study 11429666 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 0
Study 11429666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9134634 — intervention group
Group type: EXPERIMENTAL
Intervention: New rapid plasma D-Dimer ELISA measurement
Number of subjects: 448
Study 9134634 — intervention group
Group type: COMPARATOR
Intervention: Standard plasma D-Dimer ELISA measurement
Number of subjects: 448
Study 7943832 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 56
Study 7943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.2, 0.8, 1.5, 3.0, and 4.5 ng/ml)
Number of subjects: 56
Study 7943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.63 ng/ml)
Number of subjects: 56
Study 7943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (1 ng/ml)
Number of subjects: 56
Study 7943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (3 ng/ml)
Number of subjects: 56
Study 7943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (greater than 3 ng/ml)
Number of subjects: 56
Study 3791604 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI-Act pacing
Number of subjects: 44
Study 3791604 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 44
Study 31519265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 139
Study 31519265 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Massage
Number of subjects: 139
Study 31519265 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 139
Study 28708736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 1200 mg daily for 7 days
Number of subjects: 292
Study 28708736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 24993290 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet treatment
Number of subjects: 395
Study 24993290 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face treatment
Number of subjects: 395
Study 23354007 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and pharmacological interventions
Number of subjects: 670
Study 21771216 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 16
Study 21771216 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 16
Study 19067101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab in early RA
Number of subjects: 407
Study 19067101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab in established RA
Number of subjects: 407
Study 17705687 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice-daily for 28 days
Number of subjects: 226
Study 17705687 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg twice-daily for 4 weeks followed by 10 microg for 26 weeks
Number of subjects: 226
Study 17705687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 15498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times daily for 3 months (Group Aa)
Number of subjects: 70
Study 15498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene 50 mg once daily from the 5th day of menstrual cycle for 5 days and 3 cycles (Group Ab)
Number of subjects: 70
Study 15498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene for 3 cycles (Group Ac)
Number of subjects: 70
Study 15498183 — intervention group
Group type: COMPARATOR
Intervention: Metformin only (Group B)
Number of subjects: 70
Study 15498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene 50 mg once daily for 5 days and 3 cycles (Group Ab)
Number of subjects: 70
Study 15498183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene (Group Ac)
Number of subjects: 70
Study 11133901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (3 mg/day prazosin)
Number of subjects: 12
Study 11133901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9620105 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0
Study 9620105 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfonylureas
Number of subjects: 0
Study 9620105 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 8131544 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally 3 times a day for 15 days
Number of subjects: 0
Study 8131544 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro NAC treatment at 10 micrograms/ml
Number of subjects: 0
Study 8131544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2675219 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (50 micrograms/kg)
Number of subjects: 28
Study 2675219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%, 2.5 mg/kg)
Number of subjects: 28
Study 2675219 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug administered)
Number of subjects: 28
Study 817373 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic TRH (300 mg/day)
Number of subjects: 0
Study 817373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 30963820 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPATHY questionnaire (group 1, 150 patients)
Number of subjects: 300
Study 30963820 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2, 150 patients)
Number of subjects: 300
Study 28367636 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop glucose control for 12 weeks
Number of subjects: 58
Study 28367636 — intervention group
Group type: COMPARATOR
Intervention: Sensor augmented insulin pump therapy (open loop) for 12 weeks
Number of subjects: 58
Study 25040098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% praziquantel (PZQ) ointment
Number of subjects: 65
Study 25040098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle ointment)
Number of subjects: 65
Study 23514023 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior flap anastomosis and excision of the posterior flap (Group B)
Number of subjects: 83
Study 23514023 — intervention group
Group type: COMPARATOR
Intervention: Anterior and posterior flap anastomosis (Group A)
Number of subjects: 83
Study 20560804 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) program
Number of subjects: 60
Study 20560804 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 60
Study 19120432 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp) 0.3 U/kg
Number of subjects: 19
Study 17434267 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV prevention intervention trial
Number of subjects: 3128
Study 17434267 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of infection with HIV
Number of subjects: 3128
Study 17434267 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of infection with HCV
Number of subjects: 3128
Study 17434267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influences
Number of subjects: 3128
Study 17434267 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection partner type
Number of subjects: 3128
Study 15179339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 100
Study 15179339 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 100
Study 11471396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Number of subjects: 20
Study 11471396 — intervention group
Group type: COMPARATOR
Intervention: Contemporary Treatment Approach (CTA)
Number of subjects: 20
Study 9693393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (12.5 mg, i.v.)
Number of subjects: 29
Study 9693393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clomipramine after i.v. challenge
Number of subjects: 29
Study 8968295 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL)
Number of subjects: 21
Study 8968295 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (TER)
Number of subjects: 21
Study 8968295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (FEN)
Number of subjects: 21
Study 2126915 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms, topical corticosteroid)
Number of subjects: 0
Study 2126915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, cyclooxygenase inhibitor)
Number of subjects: 0
Study 2126915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7029293 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus ADR
Number of subjects: 264
Study 7029293 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC plus RT
Number of subjects: 264
Study 7029293 — intervention group
Group type: COMPARATOR
Intervention: VAC
Number of subjects: 264
Study 7029293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pulmonary RT
Number of subjects: 264
Study 30651149 — intervention group
Group type: EXPERIMENTAL
Intervention: New regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months.
Number of subjects: 204
Study 30651149 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment regimen with second-line drugs including injectables for 20-24 months.
Number of subjects: 204
Study 28657700 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (3.75% potassium chloride)
Number of subjects: 133
Study 28657700 — intervention group
Group type: COMPARATOR
Intervention: Reference dentifrice (standard fluoride)
Number of subjects: 133
Study 25978822 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs) for reducing heavy drinking
Number of subjects: 6768
Study 25978822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6768
Study 24509422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 28
Study 24509422 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic-guided injection
Number of subjects: 28
Study 24509422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 28
Study 22515336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismembered Anderson-Hynes (A-H) pyeloplasty
Number of subjects: 50
Study 22515336 — intervention group
Group type: COMPARATOR
Intervention: Nondismembered Y-V pyeloplasty
Number of subjects: 50
Study 20547296 — intervention group
Group type: EXPERIMENTAL
Intervention: Program X intervention
Number of subjects: 124
Study 20547296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 18606285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumble strips on both sides of the center line
Number of subjects: 43
Study 18606285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed shoulders
Number of subjects: 43
Study 18606285 — intervention group
Group type: COMPARATOR
Intervention: Actual marking (center line)
Number of subjects: 43
Study 18606285 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (painted center line, post-delineators)
Number of subjects: 43
Study 15811482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor group (33 patients) with controlled fluid administration
Number of subjects: 65
Study 15811482 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (32 patients) with fluid administration only
Number of subjects: 65
Study 11821456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 635
Study 11821456 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SDC)
Number of subjects: 635
Study 11149796 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent magnetic field therapy (magnets in the form of patches)
Number of subjects: 20
Study 11149796 — intervention group
Group type: COMPARATOR
Intervention: Sham magnet patches (control group)
Number of subjects: 20
Study 8828946 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 40
Study 8828946 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (P)
Number of subjects: 40
Study 1591463 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 10
Study 1591463 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo tablet
Number of subjects: 10
Study 6377715 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of immunoglobulins (Intragam)
Number of subjects: 50
Study 6377715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunoglobulin administration)
Number of subjects: 50